Revance Therapeutics reported $7.89M in Cost of Sales for its first fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Cost Of Sales Change
Abbvie ABBV:US $ 4142M 121M
Aerie Pharmaceuticals AERI:US $ 3.74M 3.04M
ALKERMES ALKS:US 58.36M 3.2M
Bristol Myers Squibb BMY:US $ 2677M 206M
Coherus Biosciences CHRS:US $ 11.28M 1.91M
Eli Lilly And LLY:US $ 1430.5M 641.6M
Endo International Ordinary Shares ENDP:US $ 179.76M 42.71M
Horizon Pharma HZNP:US $ 230.22M 15.15M
JAZZ PHA JAZZ:US $ 124.21M 8.92M
Johnson & Johnson JNJ:US $ 7919M 321M
Merk MRK:US $ 3698M 1636M
Neurocrine Biosciences NBIX:US $ 4.8M 0.2M
Pacira Pharmaceuticals PCRX:US $ 50.63M 14.55M
Procter & Gamble PG:US $ 10802M 476M
Revance Therapeutics RVNC:US $ 7.89M 12K
Supernus Pharmaceuticals SUPN:US $ 20.46M 2.52M
Teva Pharmaceutical Industries TEVA:US $ 1958M 99M